NewZNew - Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of ...

Dr. Reddy's Laboratories launches Toripalimab in India, a groundbreaking treatment for metastatic and recurrent nasopharyngeal cancer.

Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories has launched Toripalimab in India, marking it ...

Dr. Reddy's launches Loqtorzi biosimilar in India under the brand name Zytorvi for treating adults with recurrent or ...

In 2023, Dr Reddy's signed a licensing and commercialization agreement with Shanghai Junshi Biosciences for Toripalimab which ...

Dr Reddy's Laboratories has launched toripalimab, an immune oncology drug for adults with recurrent or metastatic ...

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together ...

In 2023, Dr. Reddy's entered into a license and commercialisation agreement with Shanghai Junshi Biosciences Co. Ltd for ...

New Delhi, Nov 28 (PTI) Dr Reddy's Laboratories on Thursday said it has launched Toripalimab, a drug for the treatment of recurrent or metastatic nasopharyngeal carcinoma in India. Nasopharyngeal ...

Dr. Reddy's launches immuno-oncology drug Toripalimab in India for nasopharyngeal carcinoma, expanding access to innovative treatment.

Dr Reddy’s Laboratories launches Toripalimab, the first immuno-oncology drug for nasopharyngeal carcinoma, in India.

Dr Reddy’s Laboratories launches Toripalimab, the first immuno-oncology drug for nasopharyngeal carcinoma, in India. Toripalimab, a PD-1 inhibitor, provides a new treatment option for this rare head ...